Rectal cancer sub-clones respond differentially to neoadjuvant therapy
Treatment of locally advanced rectal cancer includes chemotherapy, radiation, and surgery but patient responses to neoadjuvant treatment are variable. We have shown that rectal tumors are comprised of multiple genetically distinct sub-clones. Unique sub-clones within tumors may harbor mutations whic...
Main Authors: | Lynn M Frydrych, Peter Ulintz, Armand Bankhead, Christopher Sifuentes, Joel Greenson, Lillias Maguire, Regina Irwin, Eric R. Fearon, Karin M Hardiman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-10-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558619302441 |
Similar Items
-
Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.
by: Karin M Hardiman, et al.
Published: (2014-01-01) -
Utility of neoadjuvant therapy in rectal GIST
by: Víctor López-López, et al. -
BIOLOGICAL MARKERS OF RECTAL CANCER NEOADJUVANT CHEMORADIOTHERAPY EFFICACY
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01) -
Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
by: Federica Papaccio, et al.
Published: (2020-12-01) -
Response to neoadjuvant treatment in rectal cancer surgery
by: Loftås, Per
Published: (2016)